Beyond First Line CDK4/6 Inhibitors (CDK4/6i) and Aromatase Inhibitors (AI) in Patients with Oestrogen Receptor Positive Metastatic Breast Cancer (ER+ MBC): The Guy's Cancer Centre Experience. Issue 4 (April 2022) - Gousis, C.; Michoglou, K.; Lowe, H.; Kapiris, M.; Angelis, V.